Microdosing Semaglutide: What's Actually Known

Somewhere between late 2024 and 2026, “microdosing” went from a fringe workaround to a product category. Telehealth companies sell it. Celebrities talk about it on podcasts. Survey data suggest about one in seven people on a GLP-1 drug is doing it.

And the entire practice rests on zero randomized trials.

That is not a rhetorical flourish. As of September 2026, there is no published randomized controlled trial testing semaglutide or tirzepatide at doses below the approved minimum for weight loss or for anything else. This article explains what microdosing actually means, why it took off, what the risks are, and what a reasonable conversation with a clinician looks like.

What does microdosing actually mean?

There is no medical definition, which is the first thing to understand [1].

In practice, microdosing means taking a dose lower than the lowest dose studied and approved for a given product. Concretely:

• Semaglutide: the lowest approved dose is 0.25 mg once weekly, which is the starting step in the Wegovy titration schedule [2]. A microdose means less than that, with discussion in the field commonly landing around 0.1 to 0.125 mg weekly, though the range varies.
• Tirzepatide: the lowest studied and approved dose is 2.5 mg. Microdosing means anything below that, whether 1 mg, 1.5 mg or 2.3 mg.

Noom’s microdose program, one of the more visible commercial offerings, starts patients at 0.2 mg of compounded semaglutide weekly and caps at 0.6 mg, roughly a quarter of the standard maximum.

Microdosing is not the same as titration. Every approved GLP-1 product starts low and steps up over weeks. Wegovy begins at 0.25 mg weekly for four weeks and titrates every four weeks to a usual maintenance dose of 2.4 mg [2]. That is in the label and it exists to help people tolerate the drug on the way to a dose that works. Microdosing means staying below the starting dose indefinitely.

It is also not the same as a clinician deciding, after monitoring, that a particular patient does well on 1 mg instead of 2.4 mg. That is individualized prescribing within the approved range.

Why did microdosing take off?

Three forces, roughly in order.

Shortages. During the semaglutide and tirzepatide supply crunches, compounding pharmacies stepped in and made smaller, more flexible doses available. Stretching a supply became a practical necessity for some people.

Cost. Compounded microdose semaglutide through telehealth platforms has been advertised at roughly $50 to $150 per month. When the trend started, that undercut FDA-approved product dramatically. It no longer does. As of September 2026, Novo Nordisk’s self-pay price through NovoCare Pharmacy, TrumpRx and partner channels is $199 a month for a new patient’s first two Wegovy pen fills and $349 a month after that, with Wegovy tablets from $149 a month depending on dose [16]. Anyone with a manufacturer savings card may pay as little as $25 a month [2]. The cost argument for microdosing has narrowed considerably, and for some people it has disappeared — which is worth recalculating before assuming a compounded microdose is the cheaper route.

Social proof. A widely shared podcast interview in October 2024 promoted microdosing as a “gamechanger.” By late 2025, Noom, Found and Hims and Hers had all launched microdose GLP-1 programs within roughly three months of each other, with celebrity spokespeople attached [1]. STAT News documented how the idea moved from patient workaround to commercial category in about a year.

There is a fourth reason that is more sympathetic: some people genuinely cannot tolerate standard doses, and some people want the appetite-quieting effect without dramatic weight loss. One board-certified obesity, neurology and headache specialist quoted by the Los Angeles Times estimated 30 to 40 percent of her roughly 5,000 patients were microdosing, and defined a microdose as the lowest dose that quiets food noise without causing significant weight loss [3].

That is a coherent goal. It is just not a goal anyone has tested in a trial.

What does the evidence actually say?

Very little, because there is very little.

Physicians and researchers quoted by STAT News in November 2025 said flatly that there is no robust clinical evidence that semaglutide or tirzepatide are effective at very small doses [1]. Reshma Ramachandran, a health services researcher and clinician at Yale School of Medicine, put it bluntly: “Essentially these patients are guinea pigs, both on the efficacy side and the safety side.”

A follow-up STAT report in May 2026 reached the same conclusion: no legitimate long-term data support the trend for weight loss or any other condition, and there is still no definition of what constitutes a microdose [4].

Cedars-Sinai’s assessment is that some people report weight loss, but there is limited clinical evidence supporting microdosing as an effective long-term weight management strategy [5].

Here is what makes the evidence gap worse: marketing claims have run far ahead of anything tested. Telehealth companies have claimed that compounded GLP-1 drugs in small doses can reduce metabolic risk, lower inflammatory markers and even lower the risk of cognitive decline [1]. None of that has been demonstrated at sub-therapeutic doses in a trial. The cognitive claim is particularly hard to defend given that oral semaglutide at a full 14 mg daily dose failed to slow Alzheimer’s disease in two phase 3 trials covering 3,808 people.

What is known about full doses, for comparison?

It helps to see what the approved doses actually produce, because that is the benchmark microdosing is implicitly measured against.

In the pivotal trials, semaglutide 2.4 mg weekly produced weight loss in the 15 percent range over 68 weeks. Real-world data at 1.0 mg have been reported around 16 percent over 64 weeks in some analyses, which is one reason some clinicians are comfortable individualizing within the approved range.

Below 0.25 mg, the honest answer is that nobody has measured it in a controlled setting.

There is also a durability issue that applies at any dose. In the STEP 1 trial extension, people who stopped semaglutide regained 11.6 percentage points of their lost weight by week 120, leaving a net loss of 5.6 percent [6]. A 2026 systematic review and meta-regression found weight regain after stopping follows a predictable, decelerating curve that plateaus below pre-treatment weight [7]. Whatever dose you are on, stopping has consequences.

Is microdosing safer? The case for caution

The intuitive assumption is that a smaller dose means fewer side effects. Cleveland Clinic’s clinicians argue the opposite can happen: microdosing raises the risk of overdosing and of side effects like nausea or diarrhea, and is not as effective as long-term full doses [8].

That sounds paradoxical until you think about how a microdose is physically administered.

Approved pens deliver fixed doses. They do not offer increments small enough for a microdose, so microdosing almost always means drawing a small volume from a vial with a syringe [9]. At very small volumes, small absolute errors become large relative errors. A patient converting between milligrams, milliliters and syringe units, with a concentration that varies between pharmacies, has several chances to get it wrong.

The FDA has reported compounded semaglutide errors in which patients administered five to 20 times the intended dose, some requiring hospitalization, with contributing factors including unfamiliarity with vial-and-syringe technique, unit conversion confusion and varying concentrations between pharmacies [10]. In some cases it was the health care professional, not the patient, who miscalculated the dose [17]. As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide, a count the agency notes is almost certainly an undercount because state-licensed pharmacies are not required to report [17]. The point is not that every compounded prescription is wrong. It is that small-volume dosing demands unambiguous written instructions and pharmacy-specific verification.

There is a second-order risk too. Undertreatment is a harm. If someone spends a year on a dose that does not produce clinically meaningful benefit, that is a year of cost, injections and delayed effective treatment.

The compounding problem

Almost all microdosing depends on compounded semaglutide, and the regulatory ground under compounding has shifted hard.

Compounded drugs are not FDA-approved. The agency has not reviewed them for safety, effectiveness or quality, and has raised concerns about dosing errors, contamination, impurities and inconsistent ingredients in compounded GLP-1 products [9].

Two enforcement developments matter:

• On March 3, 2026, the FDA issued 30 warning letters to telehealth companies marketing compounded GLP-1 products, alleging false or misleading advertising that blurred the line between compounded versions and FDA-approved Ozempic, Wegovy and Mounjaro [13][14]. It was the second large batch of such letters; a further wave of roughly 25 followed in June 2026.
• On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk drug substances [15]. That would close the large-scale compounding pathway permanently. The comment period has closed, and as of September 2026 no final rule had been issued.

If you are on a microdosing protocol supplied by a telehealth platform, a reasonable question to ask is which pharmacy fills your prescription and under what authority.

Maintenance microdosing: a different question

There is one version of low-dose use that deserves separate treatment.

Some clinicians report patients who reach their goal weight on 2.4 mg and then maintain on 0.5 to 1.0 mg. That is maintenance dosing within the approved range, decided by a prescriber who is watching what happens. It is not the same as starting below the lowest approved dose and staying there.

Even so, the literature describes maintenance microdosing as anecdotal. Low-dose protocols may have a role in weight maintenance after goal weight is reached, but that remains unproven. Data on tapering are similarly thin: in one analysis of patients who tapered off, a subset followed for 26 weeks after tapering to zero had roughly stable weight with an average loss of 1.5 percent after complete withdrawal, but a meaningful share restarted the drug.

The difference that matters is supervision. A dose reduction that a clinician orders, monitors and reverses if it stops working is a clinical decision. A dose someone picks themselves, from a product the FDA has not reviewed, is not.

Questions worth asking before you consider it

If you are thinking about a low-dose GLP-1 program, these questions surface most of what matters:

• What exactly am I being prescribed, at what concentration, and from which pharmacy?
• Is this a compounded product or an FDA-approved one?
• What is the written dosing instruction, in both milligrams and syringe units, for the exact vial I am receiving?
• What specific outcome are we aiming for, and how will we know within three months whether it is working?
• What happens if it is not working? Do I step up to an approved dose, or stop?
• What follow-up and monitoring comes with this program?
• What is the total monthly cost compared with an approved product under my insurance or a manufacturer cash-pay program?

A program that cannot answer the first four of those in writing is not one to hand your money to.

The bottom line

Microdosing is real, widespread and commercially entrenched. It is also unstudied, undefined and dependent on a compounded supply the FDA is actively restricting.

None of that means it cannot help any individual person. It means that if it helps you, nobody currently knows whether that is the drug, the attention, the behavior change that came with it, or chance, and nobody can tell you what happens over five years.

If cost or side effects are pushing you toward microdosing, those are real problems worth solving. They are also worth solving with a healthcare provider who can look at approved options, manufacturer cash-pay programs, dose adjustment within the label and tolerability strategies, rather than going around the evidence entirely.

Sources

1. Microdosing aims to extend the lifespan of the GLP-1 compounding market — STAT News, November 4, 2025
2. Wegovy (semaglutide) US prescribing information — Novo Nordisk
3. Microdosing Ozempic: Benefits, risks and what doctors say — Los Angeles Times, June 23, 2026
4. GLP-1 microdosing is popular, but there’s little evidence it works — STAT News, May 29, 2026
5. Microdosing Semaglutide: Does It Work for Weight Loss? — Cedars-Sinai, August 5, 2026
6. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension — Diabetes, Obesity and Metabolism, 2022
7. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression — eClinicalMedicine, March 2026
8. Should You Microdose GLP-1 Medications? — Cleveland Clinic, July 31, 2026
9. Is microdosing Ozempic actually safe? Obesity specialists weigh in — Yahoo Health, August 20, 2026
10. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products — US Food and Drug Administration
11. Is Microdosing GLP-1s Safe? What to Know Before You Try It — Hackensack Meridian Health, May 12, 2026
12. Noom Microdose GLP-1 Rx Program — Noom (commercial program page)
13. US FDA warns 30 telehealth firms over misleading ads for compounded weight-loss drugs — Reuters, March 3, 2026
14. GLP-1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters — Foley & Lardner, March 12, 2026
15. FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs — Orrick, May 2026 (on the April 30, 2026 503B bulks list proposal)
16. Save on Wegovy — savings card and self-pay terms — Novo Nordisk, accessed September 14, 2026
17. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — US Food and Drug Administration, adverse event counts current as of May 31, 2026